Virtus ETF Advisers’s LENZ Therapeutics LENZ Stock Holding History

Virtus ETF Advisers’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,309	Closed	-$66.7K	–	814
2024 Q4	$66.7K	Buy	+2,309	New	+$70.4K	0.03%	405
2022 Q2	–	Sell	-2,138	Closed	-$76K	–	480
2022 Q1	$76K	Sell	2,138 -127	-6%	-$7.95K	0.03%	345
2021 Q4	$197K	Buy	+2,265	New	+$188K	0.07%	214

Other funds holding LENZ

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Virtus ETF Advisers's LENZ Position: Q1 2025 in Review

Virtus ETF Advisers sold out of LENZ Therapeutics (LENZ) in Q1 2025, closing a stake of 2,309 shares — an estimated $66.7K sold.

Virtus ETF Advisers first reported a position in LENZ in Q4 2021 and held it in 3 quarters. The position peaked at $197K in Q4 2021. 105 funds tracked by Wall St. Rank hold LENZ as of Q1 2025.

Virtus ETF Advisers reported no remaining LENZ Therapeutics position as of Q1 2025 after selling out during the quarter.
Virtus ETF Advisers sold 2,309 LENZ Therapeutics shares in Q1 2025, an estimated $66.7K.
Virtus ETF Advisers first reported a position in LENZ Therapeutics in Q4 2021 and held it in 3 quarters.
Virtus ETF Advisers's LENZ Therapeutics position peaked at $197K in Q4 2021.
105 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.